Navigation Links
Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
Date:5/21/2010

BOSTON, May 21 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. today announced presentation of data in a poster titled "Results from a multicenter, open-label Phase 3 study to determine the safety and efficacy of gadobutrol, a macrocyclic 1.0 molar GBCA in patients referred for contrast-enhanced MRI of the central nervous system (CNS)" at the 48th Annual Meeting of the American Society of Neuroradiology (ASNR) in Boston, MA.  The results of this study of this investigational drug met all of its pre-specified primary efficacy objectives.  Gadobutrol is investigational in the United States and is not approved by the U.S. Food and Drug Administration.

This phase 3 study had four primary efficacy objectives.  In results comparing unenhanced CNS MRI versus the combined unenhanced and gadobutrol-enhanced CNS MRI, statistically significant superiority (P<0.0001) of gadobutrol images compared to unenhanced images was shown for all three individual blinded readers as well as the average blinded reader for three of the primary efficacy variables (internal morphology, degree of contrast enhancement and border delineation).  Non-inferiority was the objective for the number of lesions detected in this study and was demonstrated for two of three blinded readers, as well as the average of the blinded readers.(1)

In the study, 14 subjects (4.1%) reported at least one adverse event which the investigators considered related to gadobutrol.  No deaths were reported during the study period, and none of the subjects discontinued from the study due to an AE.  One subject experienced a serious adverse event (SAE), which was not considered by the investigator to be related to the study drug.

"This was a large mu
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
(Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... China , May 11 /PRNewswire-Asia/ -- WuXi PharmaTech ... development outsourcing company serving the,pharmaceutical, biotechnology, and medical device industries, ... , today announced its financial results for,first-quarter 2010. , ... Highlights, -- First-Quarter 2010 Net Revenues ...
... CITY , May 11 Dynatronics Corporation (Nasdaq: DYNT ) plans ... the morning of Monday, May 17, 2010 .   , ... Dynatronics has scheduled a conference call for investors later that day at ... in participating should call 800-861-4084 and use passcode: 9921511. , ...
Cached Medicine Technology:WuXi PharmaTech Announces First-Quarter 2010 Results 2WuXi PharmaTech Announces First-Quarter 2010 Results 3WuXi PharmaTech Announces First-Quarter 2010 Results 4WuXi PharmaTech Announces First-Quarter 2010 Results 5WuXi PharmaTech Announces First-Quarter 2010 Results 6WuXi PharmaTech Announces First-Quarter 2010 Results 7WuXi PharmaTech Announces First-Quarter 2010 Results 8WuXi PharmaTech Announces First-Quarter 2010 Results 9WuXi PharmaTech Announces First-Quarter 2010 Results 10WuXi PharmaTech Announces First-Quarter 2010 Results 11WuXi PharmaTech Announces First-Quarter 2010 Results 12WuXi PharmaTech Announces First-Quarter 2010 Results 13WuXi PharmaTech Announces First-Quarter 2010 Results 14WuXi PharmaTech Announces First-Quarter 2010 Results 15WuXi PharmaTech Announces First-Quarter 2010 Results 16
(Date:7/13/2014)... July 13, 2014 Carolinas Healthcare System ... location, the Carolinas HealthCare System - Anson located in ... aged Anson Community Hospital in Wadesboro. , Located on ... miles from the previous facility. Situated on a 10-acre ... includes an emergency room drop-off, helipad, healing garden, and ...
(Date:7/13/2014)... Chromatography system is a physical ... types of biological samples such as air and ... into two phase, namely mobile phase and stationary ... over the stationary phase, followed by the differential ... the separation of mixture. Chromatography system plays an ...
(Date:7/13/2014)... Micro irrigation systems are mainly utilized for agriculture ... as to maintain soil quality. The application of micro ... dominant revenue generator for manufacturers in future. The trend ... has led to the adoption of micro irrigation techniques ... massive demand for micro irrigation systems, as they reduce ...
(Date:7/13/2014)... July 13, 2014 According to ... and Computing Market by Component (processor, GPU, DSP, ... MDA, Medical), and Geography - Forecast and Analysis ... Mobile Processing & Computing Market is expected to ... CAGR of 20.75% from 2014 to 2020. , ...
(Date:7/13/2014)... The Pearland, Texas location of The Little Gym, a ... to 12 years of age that offers everything from gymnastics, ... Summer Camps, is now under new ownership. , Kevin Berry ... spending over six years at The Little Gym of Bellaire ... Berry has over ten years of experience working with children, ...
Breaking Medicine News(10 mins):Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2
... ... maintenance medium for human embryonic and induced pluripotent stem cells. , ... Vancouver, BC (PRWEB) October 13, 2009 ... TeSR™2 , a defined, animal-protein free maintenance medium for human embryonic and induced ...
... ... and Encodes Specific Energy Frequencies into Ionized Alkaline Water for Optimum Health and Well-Being ... Carlsbad, California ... on our planet, but it,s finally getting a new high-tech upgrade with the launch ...
... increasingly common as a first line of treatment for patients ... not be necessary, according to a new study by researchers ... study shows that the condition, known as renal artery stenosis, ... percentage of cases and does not always necessitate a surgical ...
... Oct. 13 The following is a statement from ... BlueShield, regarding the Senate Finance Committee vote today on the ... to be cautiously optimistic that an economically sustainable health care ... is an important step toward ensuring long-term health care security ...
... Make Simple Changes, Transforming an Entire Community , ALBERT ... Vitality Project sponsored by United Health Foundation today ... Albert Lea increased an average of 3.1 years per ... The project was designed to inspire residents to take ...
... Insurance Plans (AHIP) President and CEO Karen Ignagni released ... reform legislation in the Senate Finance Committee: , "We ... all Americans, improves quality, and puts the health care ... have proposed guaranteed coverage, elimination of pre-existing condition exclusions, ...
Cached Medicine News:Health News:STEMCELL Technologies Inc. Announces Release of Defined, Animal-Protein Free Maintenance Medium for hESCs and hiPSCs 2Health News:LIFE Ionizers&#8482; Launches 2010 Next Generation Alkaline Water Ionizers with Energy Frequency Technology&#8482; 2Health News:LIFE Ionizers&#8482; Launches 2010 Next Generation Alkaline Water Ionizers with Energy Frequency Technology&#8482; 3Health News:LIFE Ionizers&#8482; Launches 2010 Next Generation Alkaline Water Ionizers with Energy Frequency Technology&#8482; 4Health News:Study questions need for routine intervention in patients with renovascular disease 2Health News:Study questions need for routine intervention in patients with renovascular disease 3Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 2Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 3Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 4Health News:Albert Lea Residents Add 3.1 Years of Life Expectancy 5Health News:AHIP Statement on Passage of Senate Finance Committee Legislation 2
Curved shafts with 0.5 mm, 1 x 2 teeth. Serrated handle with thumb catch lock and polished finish....
Gently curved shafts with pierse tips. Round, knurled handle for finger tip rotation. Excellent for atramatic grasp of corneal flap. Made in titanium....
Narrow 12 mm jaws with fine teeth. Serrated handle with polished finish....
Straight shafts with curved 1 x 2 teeth. Serrated handle with polished finish....
Medicine Products: